Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
281 to 300 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics. | Cancer Lett | 2026 | 41730382 | PubTator, text mining | PubMed |
| The role of antibody-drug conjugates in the treatment of lung cancer. | Front Oncol | 2026 | 41727667 | PubTator, text mining | PubMed |
| Diversity and function of tumor-associated macrophages in brain metastases: mechanisms and therapeutic prospects. | Front Immunol | 2026 | 41727473 | PubTator, text mining | PubMed |
| Sacituzumab tirumotecan (sac-TMT/MK-2870/SKB264): a novel antibody-drug conjugate in breast cancer. | Oncol Rev | 2026 | 41726150 | PubTator, text mining | PubMed |
| Real-world treatment patterns and sequencing in patients with advanced / metastatic HR+/HER2- breast cancer in Europe and the United States. | Breast | 2026 | 41719678 | PubTator, text mining | PubMed |
| Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study. | Oncologist | 2026 | 41719193 | PubTator, text mining | PubMed |
| Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers. | Mol Ther Oncol | 2026 | 41716468 | PubTator, text mining | PubMed |
| TROP2-targeted NIR-II fluorescence imaging for visualizing surgical margins and metastatic sentinel lymph nodes in breast cancers. | Proc Natl Acad Sci U S A | 2026 | 41712645 | PubTator, text mining | PubMed |
TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer: Almost a 3-month improvement was seen in median PFS for patients assigned to sacituzumab govitecan in comparison to those assigned to chemotherapy. | Cancer | 2026 | 41712613 | PubTator, text mining | PubMed |
| Illustrating a multidimensional roadmap using biomarkers and therapeutics to reshape outcomes in gastroesophageal cancer. | Ther Adv Med Oncol | 2026 | 41709926 | PubTator, text mining | PubMed |
| Quantitative Assays for TROP2 Measurement in Breast Cancer and Comparison to H-Score. | Appl Immunohistochem Mol Morphol | 2026 | 41709478 | PubTator, text mining | PubMed |
| Cellular determinants of parvovirus B19 susceptibility in the human placenta. | PLoS Pathog | 2026 | 41706746 | PubTator, text mining | PubMed |
| CD44v9 as a therapeutic target for antibody-drug conjugate in advanced breast cancer. | Biomed Pharmacother | 2026 | 41702764 | PubTator, text mining | PubMed |
| Optimal Dosage Justification for Datopotamab Deruxtecan in HR-Positive/HER2-Negative Breast Cancer Through Model-Informed Drug Development Approaches. | Clin Transl Sci | 2026 | 41691539 | PubTator, text mining | PubMed |
| Is there a future for Trop-2-targeted ADCs in urothelial carcinoma? | Ann Oncol | 2026 | 41690723 | PubTator, text mining | PubMed |
| [Progress of treatment of new targets in gastric cancer]. | Zhonghua Wei Chang Wai Ke Za Zhi | 2026 | 41688201 | PubTator, text mining | PubMed |
| TROP2 expression is associated with early stage and favorable prognosis in upper tract urothelial carcinoma. | World J Urol | 2026 | 41686301 | PubTator, text mining | PubMed |
| Bioengineering of extracellular vesicles with scaffold proteins for drug delivery. | J Nanobiotechnology | 2026 | 41680844 | PubTator, text mining | PubMed |
| Expression of Nectin-4 and Trop-2 in upper tract urothelial carcinoma: implications for biomarker-driven antibody-drug conjugate therapy. | J Pathol Clin Res | 2026 | 41680099 | PubTator, text mining | PubMed |
| TROP2-Targeted Therapeutics in Development to Treat Gastrointestinal Tumors. | Mol Diagn Ther | 2026 | 41670877 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=15